4.2 Review

Peptide vaccination therapy: Towards the next generation

期刊

PATHOLOGY INTERNATIONAL
卷 66, 期 10, 页码 547-553

出版社

WILEY-BLACKWELL
DOI: 10.1111/pin.12438

关键词

antibody recognizing HLA/peptide complex; cancer stem cell antigen; carcinoma; clinical trial; memory T stem cell; peptide vaccination; sarcoma

资金

  1. JSPS KAKENHI [16H05451]
  2. Takeda Science Foundation
  3. Cell Science Research Foundation
  4. Grants-in-Aid for Scientific Research [16H05451] Funding Source: KAKEN

向作者/读者索取更多资源

The aim of peptide vaccination therapy is to stimulate and activate peptide-specific T cells to reject tumor cells. This strategy has been promoted by the discovery of tumor-associated antigens recognized by T cells. Peptide vaccination therapy can induce immune responses in some cancer patients but the objective clinical response rates are still low. To improve of the efficacy of peptide vaccination therapy: (i) cancer stem cell antigens specifically expressed in carcinoma/sarcoma stem-like cells but not in normal cells are needed; (ii) peptide vaccination therapy should be performed in the earlier stages; and (iii) memory T stem cells should be regulated to maintain long-lasting immune responses to the peptide vaccination.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Biology

Less correlation between mismatch repair proteins deficiency and decreased expression of HLA class I molecules in endometrial carcinoma: a different propensity from colorectal cancer

Tasuku Mariya, Terufumi Kubo, Yoshihiko Hirohashi, Junko Yanagawa, Yuta Tabuchi, Kazuhiko Matsuo, Kiyoshi Furumura, Rena Morita, Munehide Nakatsugawa, Takayuki Kanaseki, Tomohide Tsukahara, Tadashi Hasegawa, Tsuyoshi Saito, Toshihiko Torigoe

Summary: In a study on endometrial cancer patients, it was found that dMMR was not correlated with the expression level of HLA class I molecules, while intact expression of HLA class I molecules was associated with p53 overexpression. Neither dMMR nor decreased expression of HLA class I molecules were prognostic factors in endometrial cancer.

MEDICAL MOLECULAR MORPHOLOGY (2021)

Article Oncology

Spatiotemporal metabolic dynamics of the photosensitizer talaporfin sodium in carcinoma and sarcoma

Takuma Saito, Tomohide Tsukahara, Takeshi Suzuki, Iyori Nojima, Hiroki Tadano, Noriko Kawai, Terufumi Kubo, Yoshihiko Hirohashi, Takayuki Kanaseki, Toshihiko Torigoe, Liming Li

Summary: Talaporfin is taken up by cells via endocytosis and degraded in lysosomes. High levels of ATP are essential for the endocytosis process, and the activation of K-Ras signaling regulates the uptake of talaporfin.

CANCER SCIENCE (2021)

Article Oncology

Identification of characteristic subepithelial surface granulomatosis in immune-related adverse event-associated enterocolitis

Terufumi Kubo, Yoshihiko Hirohashi, Yoshiko Keira, Mayuko Akimoto, Tatsuru Ikeda, Noriaki Kikuchi, Hiroyuki Iwaki, Tomoki Kikuchi, Masahiko Obata, Rena Morita, Kiyoshi Kasai, Keiko Segawa, Tomohide Tsukahara, Takayuki Kanaseki, Kenji Murata, Yasuhiro Kikuchi, Tomoyo Shinkawa, Tadashi Hasegawa, Toshihiko Torigoe

Summary: ICIs treatment may induce enterocolitis, characterized by ulcerative colitis-like and graft vs host disease-like patterns. A new characteristic, subepithelial surface granulomatosis (SSG), observed in both patterns, could be a surrogate marker of systemic anticancer immune activation. Prospective studies with larger sample sizes are recommended for further validation.

CANCER SCIENCE (2021)

Article Oncology

GRIK2 is a target for bladder cancer stem-like cell-targeting immunotherapy

Haruka Miyata, Yoshihiko Hirohashi, Shuhei Yamada, Junko Yanagawa, Aiko Murai, Shinichi Hashimoto, Serina Tokita, Kanta Hori, Takashige Abe, Terufumi Kubo, Tomohide Tsukahara, Takayuki Kanaseki, Nobuo Shinohara, Toshihiko Torigoe

Summary: Recent studies have shown that treatment-resistant cancer stem-like cells can be targeted by cytotoxic T lymphocytes, with a specific antigenic peptide (LMYDAVHVV) derived from GRIK2 being identified as a potential novel target for bladder CSC/CIC immunotherapy.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2022)

Article Oncology

Tumor-infiltrating CD8(+) T cells recognize a heterogeneously expressed functional neoantigen in clear cell renal cell carcinoma

Masahiro Matsuki, Yoshihiko Hirohashi, Munehide Nakatsugawa, Aiko Murai, Terufumi Kubo, Shinichi Hashimoto, Serina Tokita, Kenji Murata, Takayuki Kanaseki, Tomohide Tsukahara, Sachiyo Nishida, Toshiaki Tanaka, Hiroshi Kitamura, Naoya Masumori, Toshihiko Torigoe

Summary: ICIs are used in cancer immunotherapy to block certain pathways, but low response rates and tumor heterogeneity can lead to resistance. This study found that the specificity of TILs in RCC may be related to gene mutations and reactivity, suggesting heterogenous tumors may have diverse gene mutations and responses to TILs.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2022)

Article Medicine, Research & Experimental

Proteogenomic identification of an immunogenic HLA class I neoantigen in mismatch repair deficient colorectal cancer tissue

Tomomi Hirama, Serina Tokita, Munehide Nakatsugawa, Kenji Murata, Yasuhito Nannya, Kazuhiko Matsuo, Hidetoshi Inoko, Yoshihiko Hirohashi, Shinichi Hashimoto, Seishi Ogawa, Ichiro Takemasa, Noriyuki Sato, Fumitake Hata, Takayuki Kanaseki, Toshihiko Torigoe

Summary: The study identified a rare neoantigen in mismatch repair-deficient colorectal cancer tissue, which was associated with abundant tumor-infiltrating lymphocytes and an inflamed gene expression status. CD8(+) TILs predominantly recognized the detected neoantigen and exhibited functional and specific responses.

JCI INSIGHT (2021)

Article Biochemistry & Molecular Biology

High aldehyde dehydrogenase 1 activity is related to radiation resistance due to activation of AKT signaling after insulin stimulation in prostate cancer

Takahito Wakamiya, Yoshihiko Hirohashi, Aiko Murai, Junko Yanagawa, Yuka Mizue, Terufumi Kubo, Shinichi Hashimoto, Kenji Murata, Takayuki Kanaseki, Tomohide Tsukahara, Sachiyo Nishida, Yasuo Kohjimoto, Isao Hara, Toshihiko Torigoe

Summary: The ALDH1-high prostate cancer stem-like cells (CSCs) exhibit heterogeneity in tumorigenicity and resistance to radiation and chemotherapy, along with lower levels of phosphorylated AKT. Insulin can activate AKT signaling in these cells, leading to resistance to radiation and chemotherapy. These findings suggest a potential mechanism for treatment resistance in prostate cancer.

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2022)

Article Immunology

Palladium-Induced Temporal Internalization of MHC Class I Contributes to T Cell-Mediated Antigenicity

Koyu Ito, Takayuki Kanaseki, Serina Tokita, Toshihiko Torigoe, Noriyasu Hirasawa, Kouetsu Ogasawara

Summary: Palladium (Pd) is a widely used metal in dental restorations, but it can cause serious allergic reactions. Studies show that Pd treatment alters peptide presentation on MHC class I, leading to T cell-mediated antigenicity in Pd allergy.

FRONTIERS IN IMMUNOLOGY (2021)

Article Oncology

Identification of Neoantigens in Two Murine Gastric Cancer Cell Lines Leading to the Neoantigen-Based Immunotherapy

Koji Nagaoka, Changbo Sun, Yukari Kobayashi, Takayuki Kanaseki, Serina Tokita, Toshihiro Komatsu, Kazuhiro Maejima, Junichiro Futami, Sachiyo Nomura, Keiko Udaka, Hidewaki Nakagawa, Toshihiko Torigoe, Kazuhiro Kakimi

Summary: Despite the success of immune checkpoint inhibitors (ICI) in treating solid cancers, most gastric cancer patients are resistant to ICI monotherapies. This study characterized two murine gastric cancer cell lines, YTN2 and YTN16, and identified new antigens. The findings suggest that combination immunotherapy can effectively inhibit gastric cancer growth, providing a basis for the development of novel combination immunotherapies.

CANCERS (2022)

Article Gastroenterology & Hepatology

HLA Class I Analysis Provides Insight Into the Genetic and Epigenetic Background of Immune Evasion in Colorectal Cancer With High Microsatellite Instability

Masahito Kawazu, Toshihide Ueno, Koichi Saeki, Nicolas Sax, Yosuke Togashi, Takayuki Kanaseki, Keigo Chida, Fumishi Kishigami, Kazuhito Sato, Shinya Kojima, Masafumi Otsuka, Akihito Kawazoe, Hitomi Nishinakamura, Maeda Yuka, Yoko Yamamoto, Kazuo Yamashita, Satoshi Inoue, Tokiyoshi Tanegashima, Daisuke Matsubara, Kenta Tane, Yosuke Tanaka, Hisae Iinuma, Yojiro Hashiguchi, Shoichi Hazama, Seik-Soon Khor, Katsushi Tokunaga, Masahiro Tsuboi, Toshiro Niki, Masatoshi Eto, Kohei Shitara, Toshihiko Torigoe, Soichiro Ishihara, Hiroyuki Aburatani, Hiroshi Haeno, Hiroyoshi Nishikawa, Hiroyuki Mano

Summary: This study analyzed mutations in HLA-ABC genes in colorectal cancers and found a subtype of tumors with reduced lymphocyte infiltration due to decreased expression of HLA-ABC genes. Patients with these tumors had shorter survival time, despite having a higher tumor mutation burden, suggesting a counterbalance between immunogenic effects and weakened immunoreactivity. Various genetic and epigenetic alterations led to reduced expression of HLA-ABC genes.

GASTROENTEROLOGY (2022)

Article Oncology

Combined chemoradiotherapy and programmed cell death-ligand 1 blockade leads to changes in the circulating T-cell receptor repertoire of patients with non-small-cell lung cancer

Masanori Someya, Serina Tokita, Takayuki Kanaseki, Mio Kitagawa, Tomokazu Hasegawa, Takaaki Tsuchiya, Yuki Fukushima, Toshio Gocho, Yoh Kozuka, Shoh Mafune, Yutaro Ikeuchi, Mamoru Takahashi, Keigo Moniwa, Kazuhiko Matsuo, Tadashi Hasegawa, Toshihiko Torigoe, Koh-ichi Sakata

Summary: This study analyzed the T-cell receptor sequences in the peripheral blood of five patients with non-small-cell lung cancer (NSCLC) and observed the synergistic action of CRT and PD-L1 blockade on T cells. The expansion and alteration of T-cell clonotypes were observed in cases with a complete response, while no expansion or alteration of clonotypes was observed in cases with progressive disease.

CANCER SCIENCE (2022)

Article Oncology

Cisplatin-induced HSF1-HSP90 axis enhances the expression of functional PD-L1 in oral squamous cell carcinoma

Takashi Sasaya, Terufumi Kubo, Kenji Murata, Yuka Mizue, Kenta Sasaki, Junko Yanagawa, Makoto Imagawa, Hirotaka Kato, Tomohide Tsukahara, Takayuki Kanaseki, Yasuaki Tamura, Akihiro Miyazaki, Yoshihiko Hirohashi, Toshihiko Torigoe

Summary: This study investigates the effects of cisplatin on the immunotherapy response of oral squamous cell carcinoma (OSCC) and finds that cisplatin increases the surface levels of PD-L1 on OSCC cells but does not alter gene and total protein expression levels. Moreover, cisplatin-induced PD-L1 attenuates the cytotoxic T lymphocyte reaction to OSCC.

CANCER MEDICINE (2023)

Article Oncology

Exploring olfactory receptor family 7 subfamily C member 1 as a novel oral cancer stem cell target for immunotherapy

Sho Miyamoto, Yoshihiko Hirohashi, Rena Morita, Akihiro Miyazaki, Kazuhiro Ogi, Takayuki Kanaseki, Kentaro Ide, Jumpei Shirakawa, Tomohide Tsukahara, Aiko Murai, Takashi Sasaya, Kazushige Koike, Shinichiro Kina, Toshihiro Kawano, Takahiro Goto, Edward Hosea Ntege, Yusuke Shimizu, Toshihiko Torigoe

Summary: Despite advances in cancer therapies, the mortality rate of oral cancer has not improved in the past three decades. Oral cancers contain a subpopulation of cancer stem cells (CSCs) that contribute to cancer infiltration, recurrence, metastasis, and drug resistance. Cytotoxic CD8+ T lymphocytes (CTLs) play a crucial role in targeting CSCs and regulating cancer progression. This study investigates the potential of olfactory receptor family 7 subfamily C member 1 (OR7C1) as a target for CSC-targeted immunotherapy in oral cancer and finds that OR7C1 is expressed only in oral CSCs and is effectively recognized by CTLs.

CANCER SCIENCE (2023)

Article Medicine, Research & Experimental

Proteogenomic identification of an immunogenic antigen derived from human endogenous retrovirus in renal cell carcinoma

Shin Kobayashi, Serina Tokita, Keigo Moniwa, Katsuyuki Kitahara, Hiromichi Iuchi, Kazuhiko Matsuo, Hidehiro Kakizaki, Takayuki Kanaseki, Toshihiko Torigoe

Summary: CD8+ T cells can recognize and eliminate tumor cells by targeting tumor antigens displayed by HLA class I molecules. In this study, the presence of immunogenic hERV antigens in renal cell carcinoma tissues was identified, and their potential clinical applications in patients with RCC were suggested.

JCI INSIGHT (2023)

Review Immunology

Immunopathological basis of immune-related adverse events induced by immune checkpoint blockade therapy

Terufumi Kubo, Yoshihiko Hirohashi, Tomohide Tsukahara, Takayuki Kanaseki, Kenji Murata, Rena Morita, Toshihiko Torigoe

Summary: Despite the success of cancer immunotherapy using immune checkpoint inhibitors, the nonspecific release of immunosuppressive mechanisms can lead to immune-related adverse events (irAEs) that significantly impact patients' quality of life. Proper management of irAEs is crucial for the advancement of reliable cancer immunotherapies. IrAEs resemble autoimmune diseases but often have distinct features, and while the detailed pathogenesis remains unclear, numerous studies are providing insights into this phenomenon.

IMMUNOLOGICAL MEDICINE (2022)

暂无数据